Healthesystems is attending and sponsoring the Kids’ Chance National Conference, a national gathering of the Kids’ Chance community.
Healthesystems is attending the IRSG Conference, which is designed for leaders in the insurance, medical, and rehabilitation fields.
Approval Date: Apr 2024
A biosimilar of Stelara®, this drug is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis
Approval Date: Mar 2024
A long-acting, atypical antipsychotic indicated for the treatment of schizophrenia
Approval Date: Mar 2024
A first-in-class biologic indicated for the treatment of pulmonary arterial hypertension to increase exercise capacity and reduce the risk of clinical worsening events
Approval Date: Mar 2024
Indicated for the treatment of pulmonary arterial hypertension, both in patients who are treatment naïve or who are already on an ERA, PDE5 inhibitor or both
Approval Date: Mar 2024
Indicated for the treatment of hypertension in combination with other antihypertensive drugs to lower blood pressure
Approval Date: Feb 2024
A biosimilar to Humira, this drug is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, ankylosing spondylitis, and plaque psoriasis
Approval Date: Dec 2023
Indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily
Approval Date: Nov 2023
Indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in obese adults, or overweight adults with at least one weight-related comorbidity
Approval Date: Nov 2023
Indicated as an adjunct to diet and exercise to improve glycemic control of type 2 diabetes
Approval Date: Nov 2023
Indicated for erosive esophagitis and the relief of heartburn associated with erosive esophagitis
